Intensity Therapeutics Inc. (NASDAQ:INTS) Short Interest Down 58.0% in July

Intensity Therapeutics Inc. (NASDAQ:INTS) was the recipient of a large drop in short interest in the month of July. As of July 31st, there was short interest totaling 68,355 shares, a drop of 58.0% from the July 15th total of 162,597 shares. Based on an average daily volume of 23,378 shares, the short-interest ratio is presently 2.9 days. Approximately 2.7% of the company’s shares are sold short.

Intensity Therapeutics Stock Down 1.0%

INTS traded down $0.04 during trading on Friday, reaching $3.96. The stock had a trading volume of 38,949 shares, compared to its average volume of 26,156. The stock’s 50 day moving average is $4.25 and its two-hundred day moving average is $5.55. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.00 and a quick ratio of 4.86. Intensity Therapeutics has a one year low of $3.51 and a one year high of $43.50.

Intensity Therapeutics (NASDAQ:INTS) last announced its earnings results on Tuesday, August 11th. The company reported ($1.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.24). On average, analysts expect that Intensity Therapeutics will post -2.7 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on INTS shares. Citigroup reaffirmed a “buy” rating on shares of Intensity Therapeutics in a research note on Tuesday. Benchmark reissued a “speculative buy” rating on shares of Intensity Therapeutics in a research note on Wednesday, May 20th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Intensity Therapeutics in a report on Tuesday, July 21st. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $37.50.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. Geode Capital Management LLC grew its holdings in Intensity Therapeutics by 77.8% in the fourth quarter. Geode Capital Management LLC now owns 460,248 shares of the company’s stock worth $189,000 after purchasing an additional 201,357 shares during the period. Legacy Advisors LLC bought a new position in shares of Intensity Therapeutics during the fourth quarter valued at approximately $63,000. State Street Corp lifted its holdings in shares of Intensity Therapeutics by 839.3% during the fourth quarter. State Street Corp now owns 136,200 shares of the company’s stock valued at $56,000 after purchasing an additional 121,700 shares during the last quarter. Corient Private Wealth LLC purchased a new position in shares of Intensity Therapeutics during the fourth quarter valued at approximately $41,000. Finally, Jane Street Group LLC bought a new stake in shares of Intensity Therapeutics in the 4th quarter worth approximately $26,000. 3.74% of the stock is owned by hedge funds and other institutional investors.

About Intensity Therapeutics

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.